| |
 |
 |
| Company Name |
Novartis (Taiwan) Co., Ltd. |
| Protocol Number |
CENA713BTW03 |
| Title of Study |
A 48-week, prospective, non-interventional, observational post-marketing surveillance study to evaluate the cognitive, behavior and ability of function in patients with Alzheimer’s disease who receive a new prescription for rivastigmine |
| Primary Objective |
To observe the changes in Mini-Mental State Examination (MMSE) and Clinical Dementia Rating (CDR) scores in patients treated with Exelon® at Week 48 versus baseline |
| Number of Sites |
4 |
| Period of Study |
from 2010-07-01 to 2013-12-31 |
| Number of Patients |
200 |
| IRB Approval Date |
18-Jun-2010 |
| Publication Plan / Date |
31-Dec-2014 |
|
|
|
|
